GlassScriptPhysician profile
Priti Vohra
NPI 1558524017
$15,948.01
in general payments reported to CMS, 2019-2025
32 companies · $298 in 2025
The $298 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,069 · 2020: $2,235 · 2021: $4,457 · 2022: $4,060 · 2023: $1,499 · 2024: $330 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,121 · Travel and Lodging: $6.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,121.12 |
| Travel and Lodging | $6.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,706.92 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Nevro Corp. | $3,121.55 | 2019-2024 | Senza |
| Abbvie INC. | $1,848.37 | 2021-2025 | Botox, Qulipta |
| Medtronic USA, INC. | $1,111.37 | 2019-2020 | |
| Abbott Laboratories | $868.78 | 2019-2024 | Proclaim |
| Medtronic, INC. | $762.94 | 2021-2024 | Intellis Adaptivestim |
| Allergan, INC. | $761.71 | 2019-2022 | |
| Horizon Therapeutics Plc | $740.07 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $373.00 | 2022 | |
| Pfizer INC. | $369.14 | 2019-2023 | |
| Scilex Pharmaceuticals INC. | $314.07 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $273.68 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $237.54 | 2021 | |
| Ibsa Pharma INC. | $215.49 | 2021-2023 | Tirosint, Licart |
| Collegium Pharmaceutical, INC. | $176.60 | 2019-2023 | Belbuca |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Painteq LLC | $171.25 | 2021 | |
| Vertos Medical, INC. | $134.16 | 2022-2023 | Mild Device Kit |
| Relievant Medsystems, INC. | $129.98 | 2021-2022 | |
| Amgen INC. | $128.43 | 2024 | Evenity |
| Fidia Pharma USA INC. | $80.84 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $63.28 | 2023 | Seglentis |
| Biodelivery Sciences International, INC. | $54.26 | 2021 | |
| Vertical Pharmaceuticals, LLC | $51.18 | 2019 | |
| Assertio Therapeutics, INC. | $49.64 | 2020 | |
| Shionogi INC | $46.66 | 2019 | |
| Pacira Therapeutics, INC. | $41.91 | 2019-2021 | |
| Bioventus LLC | $35.90 | 2020-2023 | Supartz Fx Sodium Hyaluronate |
| Nalu Medical, INC. | $17.75 | 2021 | |
| Sentynl Therapeutics, INC. | $17.03 | 2019 | |
| Almatica Pharma LLC | $16.79 | 2021 | |
| Redhill Biopharma INC. | $14.92 | 2020 | |
| Lilly USA, LLC | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priti Vohra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.